Tailong

Henan Tailong Pharmaceutical is a leading Chinese pharmaceutical enterprise specializing in the development, production, and sale of Traditional Chinese Medicine (TCM) and modern chemical drugs. The company's core product line is anchored by the Shuanghuanglian series, which is a staple in China for treating upper respiratory tract infections and viral diseases. In addition to its manufacturing strengths, Tailong has diversified its business model to include pharmaceutical R&D services through its contract research organization (CRO) subsidiary, Beijing M-Bridge. The company is publicly traded on the Shanghai Stock Exchange and operates several GMP-certified production facilities. Its strategic focus remains on integrating traditional herbal wisdom with modern pharmaceutical standards to address public health needs.